Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
Biomarkers
Checkpoint inhibitors
Combination therapy
Immunotherapy
Tumor microenvironment
Vaccine
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
20 07 2023
20 07 2023
Historique:
received:
22
06
2023
accepted:
06
07
2023
medline:
23
10
2023
pubmed:
21
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th-December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.
Identifiants
pubmed: 37475035
doi: 10.1186/s12967-023-04329-7
pii: 10.1186/s12967-023-04329-7
pmc: PMC10360352
doi:
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
488Informations de copyright
© 2023. The Author(s).
Références
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817394
Nat Med. 2022 May;28(5):946-957
pubmed: 35484264
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Sci Adv. 2020 Jul 1;6(27):
pubmed: 32937437
Cell. 2022 Aug 4;185(16):2918-2935.e29
pubmed: 35803260
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
Oncotarget. 2015 May 10;6(13):11310-26
pubmed: 25888637
Nat Commun. 2022 Jul 25;13(1):4298
pubmed: 35879302
J Clin Oncol. 2023 Jul 1;41(19):3486-3492
pubmed: 37071838
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
J Clin Oncol. 2022 May 10;40(14):1562-1573
pubmed: 35258987
Blood. 2023 Jun 29;141(26):3153-3165
pubmed: 37130030
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
JAMA Oncol. 2023 Jan 1;9(1):51-60
pubmed: 36394839
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lancet Oncol. 2022 May;23(5):659-670
pubmed: 35427471
Nat Med. 2022 Sep;28(9):1860-1871
pubmed: 36097223
JAMA Oncol. 2021 May 1;7(5):744-748
pubmed: 33764387
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34168003
J Transl Med. 2023 May 11;21(1):318
pubmed: 37170241
Cell. 2021 Dec 9;184(25):6081-6100.e26
pubmed: 34861191
J Exp Med. 2018 Jan 2;215(1):5-7
pubmed: 29269561
Blood. 2022 Aug 4;140(5):491-503
pubmed: 35476848
Nat Med. 2022 Oct;28(10):2133-2144
pubmed: 36175679
Dig Liver Dis. 2021 Mar;53(3):318-323
pubmed: 33359404
Gut. 2018 Feb;67(2):320-332
pubmed: 27797936
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
J Clin Invest. 2021 Jul 15;131(14):
pubmed: 34138753
Nat Med. 2022 Sep;28(9):1848-1859
pubmed: 36097221
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
Ann Oncol. 2022 Oct;33(10):1052-1060
pubmed: 35764271
J Clin Oncol. 2023 Jul 20;41(21):3767
pubmed: 37159880
Clin Cancer Res. 2017 Feb 1;23(3):707-716
pubmed: 27496866
BMC Cancer. 2022 Sep 20;22(1):998
pubmed: 36127638
J Immunol. 2004 Dec 15;173(12):7125-30
pubmed: 15585832
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34907910
Nat Commun. 2021 Dec 15;12(1):7304
pubmed: 34911934
Clin Cancer Res. 2021 Feb 15;27(4):928-932
pubmed: 32967940
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
Sci Immunol. 2021 Apr 9;6(58):
pubmed: 33837124
Cancer Immunol Res. 2021 Jul;9(7):790-810
pubmed: 33990375
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36600653
Nat Cancer. 2021 Sep;2(9):919-931
pubmed: 34917944
Lancet Oncol. 2021 Jun;22(6):824-835
pubmed: 34015311
Clin Cancer Res. 2021 Jul 1;27(13):3744-3756
pubmed: 33986022
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
JCI Insight. 2023 Apr 24;8(8):
pubmed: 36881480
Cancer. 2022 Jun 1;128(11):2085-2097
pubmed: 35383908
F1000Res. 2020 Aug 24;9:1028
pubmed: 33214875
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Mol Cancer Ther. 2021 Jan;20(1):150-160
pubmed: 33037138
Cancer Discov. 2021 Sep;11(9):2186-2199
pubmed: 33820778
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Immunol Rev. 2019 Jul;290(1):127-147
pubmed: 31355495
Science. 2020 Dec 11;370(6522):1328-1334
pubmed: 33303615
Cancer. 2018 Sep 15;124(18):3706-3714
pubmed: 29975414
J Clin Oncol. 2020 Jun 1;38(16):1814-1823
pubmed: 32275468
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Nat Commun. 2020 Mar 19;11(1):1459
pubmed: 32193378
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Eur J Cancer. 2020 Aug;135:211-220
pubmed: 32599411
Lancet Oncol. 2021 Jul;22(7):931-945
pubmed: 34051178
Cancer Discov. 2017 Jul;7(7):694-703
pubmed: 28288993
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
N Engl J Med. 2022 Dec 15;387(24):2220-2231
pubmed: 36507690
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33678606
Clin Cancer Res. 2021 Nov 1;27(21):5993-6000
pubmed: 34376536
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30730851
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
N Engl J Med. 2021 Jun 3;384(22):2102-2114
pubmed: 34077643
Cancer Discov. 2022 Jun 2;12(6):1435-1448
pubmed: 35398880
Lancet. 2020 May 16;395(10236):1547-1557
pubmed: 32416780
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Blood. 2005 Jan 1;105(1):241-50
pubmed: 15345595
Nat Commun. 2017 Dec 6;8(1):1961
pubmed: 29213079
Cancer Discov. 2020 Apr;10(4):552-567
pubmed: 32001516
Nat Rev Drug Discov. 2022 Jul;21(7):482-483
pubmed: 35145263
Gynecol Oncol. 2017 Jun;145(3):420-425
pubmed: 28392127
J Immunother Cancer. 2019 Nov 7;7(1):292
pubmed: 31699151
Oncologist. 2016 May;21(5):643-50
pubmed: 27026676
Clin Cancer Res. 2023 Feb 16;29(4):723-730
pubmed: 36595540
Lancet Oncol. 2021 Jul;22(7):1034-1046
pubmed: 34143970
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34083421
Clin Cancer Res. 2021 Apr 15;27(8):2226-2235
pubmed: 33509808
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399
Nat Commun. 2022 Jun 11;13(1):3367
pubmed: 35690611
Clin Cancer Res. 2023 Feb 1;29(3):647-658
pubmed: 36315045
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33849926